Equities researchers at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “buy” rating on the stock.
Trinity Biotech Trading Down 3.0 %
Trinity Biotech stock opened at $3.20 on Friday. The firm has a 50 day moving average of $2.24 and a 200 day moving average of $2.20. The firm has a market capitalization of $24.38 million, a price-to-earnings ratio of -1.15 and a beta of 1.31. Trinity Biotech has a 12-month low of $1.49 and a 12-month high of $5.25.
Trinity Biotech (NASDAQ:TRIB – Get Free Report) last announced its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. The business had revenue of $14.70 million for the quarter. On average, analysts predict that Trinity Biotech will post -2.17 EPS for the current year.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
See Also
- Five stocks we like better than Trinity Biotech
- Election Stocks: How Elections Affect the Stock Market
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- What is a buyback in stocks? A comprehensive guide for investors
- Has This Leading Tech Stock Halted the AI Surge?
- Stock Average Calculator
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.